Proimmunogenic impact of MEK inhibition synergizes with agonist anti-CD40 immunostimulatory antibodies in tumor therapy.
Baumann D, Hägele T, Mochayedi J, Drebant J, Vent C, Blobner S, Noll JH, Nickel I, Schumacher C, Boos SL, Daniel AS, Wendler S, Volkmar M, Strobel O, Offringa R.
Baumann D, et al. Among authors: hagele t.
Nat Commun. 2020 May 1;11(1):2176. doi: 10.1038/s41467-020-15979-2.
Nat Commun. 2020.
PMID: 32358491
Free PMC article.